Europe: the new Eldorado for buying up cannabis companies?

The he European cannabis market has the potential to be the largest in the world. For the moment, the state of the law limits its expansion, but certain types of production are already authorized: industrial hemp, of course, but also the production of medical cannabis in certain countries.

Cannabis investors are already investing large sums in European companies, setting up subsidiaries to distribute their products on the Old Continent.

This trend reflects an increasingly global approach and a focus on Europe, as evidenced by recent market movements.

Kaneh Bosm acquires Farmaken (Slovenia) and EU Cannabis (Greece)

Canadian medical cannabis producer Kaneh Bosm Bio Technology has reached an agreement to acquire the entire share capital of the Slovenian company Farmakem and the Canadian company EU Cannabis which is in the process of obtaining a license from the Greek government. By making both companies its subsidiaries, the Group has secured a solid position in the market. developing Europe.

The two companies acquired are vertically integrated, bringing together the various stages in the product value chain. They thus ensure entirely local production and distribution without the need for import/export.

Farmaken covers research and development, production, supply, distribution and marketing of pharmaceutical ingredients, medical devices and dietary supplements for the healthcare industry. cannabis and hemp.

As for EU Cannabis, its future facilities in Greece will include a 97,000m² greenhouse, a indoor cultivation and a laboratory. Its activities combine cultivation, extraction, distribution and R&D.

Farmaken has been appointed official supplier of Cebexan (a CBD-based product) to the Clinical Center of the University of Ljubljana, for 4 years, starting on January 10. The company has also recently signed an agreement with an Italian distributor specializing in the sale of CBD products, and entered into negotiations with German and European distributors.

EU Cannabis will partner and advise the Greek government in the establishment of its medical cannabis market. These investments enable Kaneh Bosm to gain a solid foothold in the Eastern European market. The company is thus expanding its global distribution network, which already includes 35,000 pharmacies in 16 different countries.

TGOD acquires Hempoland (Poland)

The Green Organic Dutchman has just acquired the entire capital of Hempoland for 7.75 million dollars (value of its shares) and has injected 10.3 million dollars for rapid European expansion. Hempoland is one of the leaders in the European CBD oil market, with CEO Maciej Kowalski a recognized expert.

Founded in 2014, the company was the first in Poland to obtain a license to grow and manufacture CBD-derived products. The company is vertically integrated: it owns 1,250 acres of cultivated land, supplying around 32,000 kilos of dried flower and 310 kilos of oil. of CBD to its extraction and manufacturing units and some 700 distribution outlets located throughout most of Europe (Poland, Austria, Holland, Germany, UK, Italy, Switzerland, Portugal, Ireland, Czech Republic, Slovenia, Lithuania, Estonia). The company also has a online platform.

TGOD's CEO is delighted with the acquisition, and it's easy to see why: the Canadian producer of medical marijuana s ambition is «to become the biggest organic cannabis brand in the world», and this acquisition is a fantastic gateway to Europe and its 750 million-strong market.

Medmen listed on the European stock exchange

At the same time, Medmen, one of America's leading cannabis that operates worldwide, announced at the beginning of the month that its shares were now listed on the Paris stock exchange. Frankfurt Stock Exchange. They were already listed in North America at Canadian Stock Exchange and the OTCQB. Now present on a European financial market, the company intends to reach out to European investors and «raise its profile internationally».

«We believe that investor interest in the cannabis industry will experience even greater momentum in Europe and beyond, and Medmen will continue to play a key role in accelerating this momentum,» said Daniel Yi, the company's Director of Corporate Communications and Investor Relations.

LGC and its partner start production in Italy

LGC Capital, an investment company operating in the global legal cannabis market, has opted for a global investment strategy and produces cannabis in Australia through the company Little Green Pharma, in Jamaica through Global Canna Labs, in Switzerland through Viridi-Unit and soon in Quebec through Tricho-Med. The company recently signed an agreement with Evolution Bnk, a Bulgarian company to produce cannabis for it in Italy.

Production has already begun at the Pavia plantation in Italy, and similar facilities are being built in Sanremo. Once the facilities are ready, their production capacity will reach around 7,000kg of dried cannabis per year. Mazen Hadda, vice-president of the group, said: «Progress in Italy is accelerating. We see Italy as a key European market for legal cannabis production».